RBC Capital analyst Conor McNamara maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and adjusts the target price from $767 to $718.
According to TipRanks data, the analyst has a success rate of 35.4% and a total average return of -9.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:
Thermo Fisher's recent quarterly performance met expectations in a period where anticipation was high. The company demonstrated strong execution amid a challenging demand scenario within the tools sector, with uncertainty looming over the timing of demand resurgence.
While Thermo Fisher's third-quarter earnings call was more optimistic than its results, there remains a positive outlook on the stock. The Life Sciences Solutions segment continues to experience bioproduction momentum, and the Laboratory Products and Biopharma Services segment does not appear to be affected by a biotech slowdown.
Thermo Fisher's core growth has been observed to be on a consistent upward trajectory quarter-over-quarter, with projections suggesting a slight increase to approximately +2.5% in the fourth quarter. Expectations on the Street for a 5% core growth by 2025 appear to be solid and justifiable. The company's defensive profile and balance sheet flexibility remain favorable.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇资本市场分析师Conor McNamara维持$赛默飞世尔 (TMO.US)$买入评级，并将目标价从767美元下调至718美元。
根据TipRanks数据显示，该分析师近一年总胜率为35.4%，总平均回报率为-9.9%。
此外，综合报道，$赛默飞世尔 (TMO.US)$近期主要分析师观点如下：
赛默飞世尔最近的季度表现符合预期，在市场高度期待的情况下。该公司在工具板块面临挑战性需求环境中表现出色，尽管需求复苏的时间仍不确定。
尽管赛默飞世尔第三季度的业绩会比预期更乐观，但仍然对股票持乐观态度。生命科学解决方案板块持续经历生物生产势头，实验室产品和生物制药服务板块似乎不受生物技术放缓影响。
赛默飞世尔的核心增长被观察到在季度间保持不断上升的轨迹，预测显示第四季度将略有增加至约+2.5%。街头对2025年的5%核心增长的预期似乎是稳固且合理的。公司的防御性特点和资产负债表灵活性仍然令人满意。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
